Chronic Pain – Pipeline Review, H2 2016

Publication Month: Feb 2020 | No. of Pages: 128 Published By: Global Markets Direct
Single User License: US $ 2000
Corporate User License: US $ 6000

Global Markets Direct’s, ‘Chronic Pain – Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Chronic Pain

The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Pain therapeutics and enlist all their major and minor projects

The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews the latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with the potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Acadia Pharmaceuticals Inc.

Adynxx, Inc.

Allergan Plc

Amorsa Therapeutics Inc.


Asana BioSciences, LLC

AskAt Inc.

Astraea Therapeutics, LLC

Axsome Therapeutics, Inc.

BioDelivery Sciences International, Inc.

Biogen Inc

Bionomics Limited

Camurus AB

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

ChironWells GmbH

Collegium Pharmaceutical, Inc.

Crinetics Pharmaceuticals, Inc.

Cyclenium Pharma, Inc.

Cytogel Pharma, LLC

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Dompe Farmaceutici S.p.A.

Echo Pharmaceuticals B.V.

Egalet Corporation

Eli Lilly and Company

Elite Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Heron Therapeutics, Inc.

INSYS Therapeutics, Inc.

Johnson & Johnson

Kareus Therapeutics, SA

KPI Therapeutics, Inc.

Kymab Limited

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Lpath, Inc.

MD Biosciences GmbH

Merck & Co., Inc.

Moberg Pharma AB

Mundipharma International Ltd

Nanomerics Ltd

Nektar Therapeutics

Neura Therapeutik, LLC

Orion Oyj

Pacira Pharmaceuticals, Inc.

Pain Therapeutics, Inc.

PeriphaGen, Inc.

Pfizer Inc.

Phosphagenics Limited

Prismic Pharmaceuticals, Inc.

Purdue Pharma LP

Relmada Therapeutics, Inc.

Ribomic Inc.


Shulov Innovative Science Ltd.

Synactix Pharmaceuticals, Inc.

Syntrix Biosystems, Inc.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd.

Trevena, Inc.

Voyager Therapeutics, Inc.

Yooyoung Pharmaceutical Co., Ltd.

Zynerba Pharmaceuticals, Inc.


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Chronic Pain Overview 12

Therapeutics Development 13

Pipeline Products for Chronic Pain - Overview 13

Pipeline Products for Chronic Pain - Comparative Analysis 14

Chronic Pain - Therapeutics under Development by Companies 15

Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22

Chronic Pain - Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Chronic Pain - Products under Development by Companies 27

Chronic Pain - Products under Investigation by Universities/Institutes 35

Chronic Pain - Companies Involved in Therapeutics Development 36

AbbVie Inc 36

Acadia Pharmaceuticals Inc. 37

Adynxx, Inc. 38

Allergan Plc 39

Amorsa Therapeutics Inc. 40

arGEN-X BV 41

Asana BioSciences, LLC 42

AskAt Inc. 43

Astraea Therapeutics, LLC 44

Axsome Therapeutics, Inc. 45

BioDelivery Sciences International, Inc. 46

Biogen Inc 47

Bionomics Limited 48

Camurus AB 49

Cara Therapeutics, Inc. 50

Centrexion Therapeutics Corp 51

ChironWells GmbH 52

Collegium Pharmaceutical, Inc. 53

Crinetics Pharmaceuticals, Inc. 54

Cyclenium Pharma, Inc. 55

Cytogel Pharma, LLC 56

Daewoong Pharmaceutical Co., Ltd. 57

Daiichi Sankyo Company, Limited 58

Dompe Farmaceutici S.p.A. 59

Echo Pharmaceuticals B.V. 60

Egalet Corporation 61

Eli Lilly and Company 62

Elite Pharmaceuticals, Inc. 63

Glenmark Pharmaceuticals Ltd. 64

Grunenthal GmbH 65

Heron Therapeutics, Inc. 66

INSYS Therapeutics, Inc. 67

Johnson & Johnson 68

Kareus Therapeutics, SA 69

KPI Therapeutics, Inc. 70

Kymab Limited 71

Laboratorios Del Dr. Esteve S.A. 72

Lohocla Research Corporation 73

Lpath, Inc. 74

MD Biosciences GmbH 75

Merck & Co., Inc. 76

Moberg Pharma AB 77

Mundipharma International Ltd 78

Nanomerics Ltd 79

Nektar Therapeutics 80

Neura Therapeutik, LLC 81

Orion Oyj 82

Pacira Pharmaceuticals, Inc. 83

Pain Therapeutics, Inc. 84

PeriphaGen, Inc. 85

Pfizer Inc. 86

Phosphagenics Limited 87

Prismic Pharmaceuticals, Inc. 88

Purdue Pharma LP 89

Relmada Therapeutics, Inc. 90

Ribomic Inc. 91

Sea4Us 92

Shulov Innovative Science Ltd. 93

Synactix Pharmaceuticals, Inc. 94

Syntrix Biosystems, Inc. 95

Teva Pharmaceutical Industries Ltd. 96

Therapix Biosciences Ltd. 97

Trevena, Inc. 98

Voyager Therapeutics, Inc. 99

Yooyoung Pharmaceutical Co., Ltd. 100

Zynerba Pharmaceuticals, Inc. 101

Chronic Pain - Therapeutics Assessment 102

Assessment by Monotherapy Products 102

Assessment by Combination Products 103

Assessment by Target 104

Assessment by Mechanism of Action 111

Assessment by Route of Administration 118

Assessment by Molecule Type 120

Drug Profiles 122

(celecoxib + tramadol hydrochloride) - Drug Profile 122

(hydrocodone bitartrate + palmidrol) - Drug Profile 124

(morphine sulfate + palmidrol) - Drug Profile 125

(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 126

(oxycodone hydrochloride + palmidrol) - Drug Profile 127

(palmidrol + pregabalin) - Drug Profile 128

A-200 - Drug Profile 129

AGN-XX - Drug Profile 130

AGN-YY - Drug Profile 131

AMS-520 - Drug Profile 132

ASN-008 - Drug Profile 133

AVLX-144 - Drug Profile 134

AXS-06 - Drug Profile 135

AYX-1 - Drug Profile 136

AYX-2 - Drug Profile 138

BBI-11008 - Drug Profile 139

bupivacaine - Drug Profile 140

bupivacaine hydrochloride - Drug Profile 142

buprenorphine hydrochloride - Drug Profile 144

buprenorphine hydrochloride depot - Drug Profile 146

buprenorphine hydrochloride ER - Drug Profile 147

buprenorphine hydrochloride long acting - Drug Profile 149

cebranopadol - Drug Profile 150

cetirizine hydrochloride + cromolyn sodium - Drug Profile 153

cetuximab - Drug Profile 154

CNTX-0290 - Drug Profile 160

CNV-3000164 - Drug Profile 161

CNV-3000223 - Drug Profile 162

CR-4056 - Drug Profile 163

CR-701 - Drug Profile 164

CRB-0089 - Drug Profile 165

Cyt-1010 - Drug Profile 166

dexmedetomidine hydrochloride - Drug Profile 168

DF-2593A - Drug Profile 170

difelikefalin - Drug Profile 171

dronabinol - Drug Profile 178

DS-1971 - Drug Profile 180

DWJ-208 - Drug Profile 181

ECP-1014 - Drug Profile 182

Egalet-003 - Drug Profile 183

fluticasone propionate - Drug Profile 184

FY-101C - Drug Profile 185

FY-103B - Drug Profile 186

GBR-900 - Drug Profile 187

Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 188

grapiprant - Drug Profile 189

HPI-201 - Drug Profile 191

HS-731 - Drug Profile 192

hydrocodone bitartrate ER - Drug Profile 193

hydrocodone bitartrate ER - Drug Profile 196

hydrocodone bitartrate ER - Drug Profile 197

hydromorphone hydrochloride - Drug Profile 198

Kindolor - Drug Profile 199

KY-1017 - Drug Profile 200

L-779976 - Drug Profile 201

lacosamide - Drug Profile 202

LEVI-04 - Drug Profile 203

levorphanol tartrate ER - Drug Profile 204

Lpathomab - Drug Profile 206

MD-354 - Drug Profile 209

Monoclonal Antibodies for Chronic Pain - Drug Profile 210

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 211

morphine sulfate ER - Drug Profile 212

MR-309 - Drug Profile 216

NET-END - Drug Profile 218

NKTR-181 - Drug Profile 219

NL-001 - Drug Profile 222

NL-002 - Drug Profile 223

NM-0127 - Drug Profile 224

Omnitram - Drug Profile 225

onabotulinumtoxin A - Drug Profile 226

OSX-300 - Drug Profile 231

OSX-300 Backups - Drug Profile 232

oxycodone hydrochloride ER - Drug Profile 233

oxycodone hydrochloride ER - Drug Profile 236

oxycodone hydrochloride ER - Drug Profile 237

oxymorphone hydrochloride - Drug Profile 239

oxymorphone hydrochloride ER - Drug Profile 240

PAC-CP - Drug Profile 241

palmidrol - Drug Profile 242

Peptide to Block Cav2.2 for CNS Disorders - Drug Profile 243

Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 244

Peptides to Target TRPV1 for Pain and Itch - Drug Profile 245

PN-6047 - Drug Profile 246

PRC-062 - Drug Profile 247

Prostatic Acid Phosphatase - Drug Profile 248

PspTx-3 - Drug Profile 249

raxatrigine hydrochloride - Drug Profile 250

RBM-005 - Drug Profile 253

REL-1017 - Drug Profile 254

SAFit2 - Drug Profile 257

Small Molecule for Chronic Pain - Drug Profile 258

Small Molecule for Chronic Pain - Drug Profile 259

Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile 260

Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile 261

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 262

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 264

Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 265

Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 266

Small Molecules for Chronic Wound Pain - Drug Profile 267

Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 268

Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile 269

Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 270

Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile 271

Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 272

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile 273

Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile 274

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 275

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 276

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 277

Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 278

Small Molecules to Block Nav

1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 279

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 280

Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 281

Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile 282

Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile 283

Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 284

Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile 285

SYN-003 - Drug Profile 286

Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 287

tanezumab - Drug Profile 288

tapentadol hydrochloride IR - Drug Profile 291

TRV-734 - Drug Profile 293

U-2902 - Drug Profile 295

UMB-425 - Drug Profile 297

Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile 298

VM-902A - Drug Profile 299

VYNAV-01 - Drug Profile 300

XT-101 - Drug Profile 301

YYC-301 - Drug Profile 302

ZEP-3 - Drug Profile 303

ZYN-001 - Drug Profile 304

Chronic Pain - Dormant Projects 305

Chronic Pain - Discontinued Products 314

Chronic Pain - Product Development Milestones 317

Featured News & Press Releases 317

Appendix 325

Methodology 325

Coverage 325

Secondary Research 325

Primary Research 325

Expert Panel Validation 325

Contact Us 325

Disclaimer 326

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets